Estrogen Balance

Estrogen Balance: A Comprehensive Reference in Nutrition and Natural-Health Context

1. Definition and Overview

The hormone estrogen is involved in both female and male reproduction, as well as numerous other biological systems including the neuroendocrine, vascular, skeletal, and immune systems. Converted from androgen via the aromatase enzyme, estrogen is indispensable to glucose homeostasis, immune robustness, bone health, cardiovascular health, fertility, and neural functions. However, estrogen is at the center of almost all human pathologies — infectious, autoimmune, metabolic, and degenerative — and both hypo- and hyper-levels of estrogen have been linked to chronic and acute diseases.

In humans, estradiol is the primary circulating estrogen hormone that mediates signals through the intracellular nucleus, plasma, and membrane-associated estrogen receptors (ERs). Four main endogenous estrogens may be distinguished: estrone (E1), estradiol (E2), estriol (E3), and estetrol (E4 — only present in pregnancy from 9 weeks of gestation). Estrone (E1) is the main type of estrogen present in the body after menopause, made primarily in adipose tissue. Estradiol (E2) is the strongest estrogen, made by the ovaries and present in the body before menopause. Estriol (E3) is the weakest estrogen, present in the body primarily during pregnancy.

The concept of estrogen balance encompasses the idea that the ratio, metabolism, and receptor activity of estrogens — not simply their absolute levels — are consequential for health. Estrogen dominance, a term used in integrative and functional medicine, describes the condition of increased estrogen levels relative to progesterone levels in the body; it may result from overproduction of estrogen, changes in estrogen metabolism and excretion, or an imbalance in the estrogen-to-progesterone ratio. Currently, estrogen dominance is not recognized as a formal medical diagnosis; clinicians may refer to it using terms such as "excess estrogen" in the context of ovarian dysfunction.

2. Estrogen's Physiological Roles and the Body Systems Involved

Estrogens play a fundamental role in the physiology of the reproductive, cardiovascular, skeletal, and central nervous systems. Estrogen actions in hypothalamic nuclei differentially control food intake, energy expenditure, and white adipose tissue distribution. Estrogen actions in skeletal muscle, liver, adipose tissue, and immune cells are involved in insulin sensitivity as well as prevention of lipid accumulation and inflammation. Estrogen actions in pancreatic islet β-cells also regulate insulin secretion, nutrient homeostasis, and survival.

17β-estradiol (E2), as the major estrogen in the body, primarily regulates energy balance via estrogen receptor alpha (ERα). Over the last two decades, it has become evident that estrogens preserve the integrity of energy homeostasis at central and peripheral levels. Estrogen deficiency, such as that caused by menopause or ovariectomy, has been linked to obesity and metabolic disorders that can be resolved or reversed by estrogen therapy.

Estrogens, a class of steroid hormones, regulate the growth, development, and physiology of the human reproductive system. They also involve the neuroendocrine, skeletal, adipogenesis, and cardiovascular systems. Estrogen signaling pathways are selectively stimulated or inhibited depending on a balance between the activities of estrogen receptor (ER)α or ERβ in target organs.

The body has two main receptors to which estrogen binds: alpha receptors that promote cell growth and beta receptors that inhibit cell growth. The metabolite 2-hydroxyestrone has multiple health benefits, working to block stronger estrogens that promote cell proliferation and possible cancer growth. Conversely, 16-hydroxyestrone increases cell proliferation. A small amount of estrogen is metabolized to 4-hydroxyestrone, which is thought to promote cancer by damaging DNA.

3. Associated Conditions and Presentations

Estrogen imbalance is implicated in many different diseases and conditions such as infertility, obesity, osteoporosis, endometriosis, and a variety of cancers. Many conditions are thought to be associated with or exacerbated by estrogen dominance, including breast and uterine cancers, fibroids, endometriosis, and polycystic ovarian syndrome.

Estrogen deficiency promotes metabolic dysfunction predisposing to obesity, the metabolic syndrome, and type 2 diabetes. While normal aging is supposed to lower estrogen levels — leading to tissue degeneration (bone, muscle, neural) and metabolite imbalance (glucose, lipid) — the increment in inflammatory agents in day-to-day life can enhance estrogen (or estrogen mimic) levels, fueling estrogen dominance. The resultant excess estrogen is associated with overexpression of estrogen receptors (ERα and ERβ), harming tissues, and potentially leading to autoimmune diseases and neoplasms.

4. Estrogen Metabolism: The Liver and Phase I/II Pathways

Estrogens are metabolized mainly in the liver, forming a biologically inactive conjugated form that is excreted in the bile and eventually enters the intestine, where they are partly excreted in the feces and urine. Estradiol is catalyzed by CYP1A1 in extrahepatic tissues and by CYP1B1 in mammary, uterus, and ovary tissues. Changes in the level of CYP isoforms would alter estrogen activity and affect the liver and target tissues. In the second phase of estrogen metabolism, hydroxylated estrogens are inactivated through conjugation reactions, including methylation, sulfation, and conjugation with glutathione. Estrogen methylation is catalyzed by catechol O-methyltransferase (COMT).

The ovaries produce estrogen in the form of the parent molecules estrone and estradiol, which can be irreversibly hydroxylated via various pathways. Hydroxylation at the C-2, C-4, or C-16 positions of the steroid ring produces estrogen metabolites that differ in their bioavailability to breast tissues and activation of estrogen receptors. Numerous studies have shown that the ratio between the different metabolites is correlated with the risk of breast cancer. A healthy estrogen balance favoring production of 2-hydroxyestrone is considered important for women's health.

5. The Gut Microbiome and the Estrobolome

Circulating estrogens are highly regulated by symbiotic bacterial activity; the human gut microbiota regulates estrogen metabolism through the "estrobolome," a collection of bacterial genes that encode enzymes like β-glucuronidases and β-glucosidases. These enzymes increase the reabsorption of active free estrogens into the bloodstream in the enterohepatic circulation, affecting circulating levels, and are important mediators of gut microbiota–host interactions.

A key estrobolome mechanism is through the function of microbial β-glucuronidases, where circulating estrogens are conjugated in the liver — reducing their reactivity — and then excreted into bile. Through enterohepatic circulation, they reach the small intestine, where β-glucuronidases deconjugate the conjugated estrogens into parent estrogens that can be reabsorbed into circulation and interact with estrogen receptors α and β in breast tissue, thereby modulating overall breast cancer risk.

Conversely, if the gut microbiota is imbalanced and microbial diversity is reduced, β-glucuronidase activity is reduced and the enterohepatic circulation is compromised, leading to a reduction in circulating estrogens. Alterations in the estrobolome can drive estrogen-mediated pathologies. While the estrobolome hypothesis is compelling, no specific microbial profile has been definitively linked to breast cancer. Research has observed lower microbial diversity and higher proportions of facultative aerobes in breast cancer cases, suggesting broad ecological shifts in the microbiome.

6. Contributing and Associated Factors

6.1 Body Fat and Adipose Tissue Aromatase

Aromatase is found in estrogen-producing cells such as white adipose tissue. Women with higher amounts of fat have higher levels of aromatase; thus, obese postmenopausal women have higher estrogen levels than lean postmenopausal women. Elevated estrogen levels are considered to be a risk factor for breast cancer.

6.2 Alcohol Consumption

Alcohol consumption may promote aromatization of androgens to estrogens, which may partly explain the observations linking alcohol consumption to higher breast cancer risk. Among women not using aromatase inhibitors, alcohol has been hypothesized to promote the aromatization of androgens to estrogen and to slow the clearance of estradiol, thereby increasing exposure to sex hormones and increasing breast cancer risk. Alcohol intake is associated with a higher risk of estrogen receptor-positive (ER+) breast cancer, presumably through its confirmed ability to increase sex hormone levels.

6.3 Xenoestrogens and Environmental Endocrine Disruptors

Bisphenol A (BPA), an environmental estrogen, is one of the most common synthetic chemicals entering the human body from plastic bottles, food packaging, and dental materials. Long-term exposure to BPA is connected with a risk of developing various diseases and endocrine disorders. Exposure to BPA, particularly during development, increases the risk of breast carcinoma, obesity, type 2 diabetes, and reproductive disorders, as well as testes carcinoma and prostate carcinoma. The effects of other xenoestrogens, such as polychlorinated biphenyls, phthalates, and dioxins, are similar or perhaps even stronger, though the exact pathophysiologic mechanisms are not yet fully clear and require further study.

Many xenoestrogens have been shown to cause obesity in animals at low-level exposures during critical periods of development. More specifically, DES and BPA have been implicated as environmental chemicals that increase fat accumulation by increasing the number of adipocytes, storage of fat within adipocytes, and facilitating obesity. Xenoestrogens can cause disruptions of the oscillating temporal patterns of nongenomic signaling elicited by endogenous estrogens. Concentration effects of xenoestrogens are nonmonotonic — a trait shared with natural hormones — making it difficult to design efficient toxicology tests to monitor their harmful effects.

6.4 Gut Dysbiosis

Interventions that alter gut microbiome diversity impact estrogen-mediated disease. The estrobolome process facilitates entero-hepatic recirculation of estrogens and has been proposed as a potential mechanism by which the gut microbiome may modulate estrogen availability. Conversely, estrogens may influence gut microbiome composition by influencing gut barrier integrity, immune response, and microbial niche conditions.

6.5 Menstrual Cycle Phase, Anovulation, and Perimenopause

Estrogen dominance can occur because of a relative deficiency in progesterone levels. When progesterone is low, even normal estrogen levels can lead to relative estrogen dominance. Progesterone deficiency can occur during the latter stages of the menstrual cycle, especially in women experiencing anovulation (lack of ovulation), or as a result of medical conditions like polycystic ovary syndrome (PCOS).

7. Nutrients, Herbs, and Natural Ingredients

7.1 Phytoestrogens

Definition and Food Sources

Phytoestrogens are naturally-occurring plant compounds that are structurally and/or functionally similar to mammalian estrogens and their active metabolites. One major class is the lignans, components of plant cell walls found in many fiber-rich foods such as berries, seeds (particularly flaxseeds), grains, nuts, and fruits. Most phytoestrogens, however, are phenolic compounds, of which the isoflavones and coumestans are the most widely researched groups. Isoflavones are most abundant in soybeans and other legumes.

The soy isoflavones genistein and daidzein, and the flaxseed lignans secoisolariciresinol and matairesinol, are among the best-characterized phytoestrogens. As weak estrogen agonists/antagonists with molecular and cellular properties similar to synthetic endocrine disruptors such as BPA, phytoestrogens provide a useful model to investigate the biological impact of endocrine disruptors in general.

Traditional Use

Soy-based foods — including tofu, tempeh, miso, and edamame — have been dietary staples in East Asian cultures for centuries and were historically associated with perceived benefits in women's health and longevity. Flaxseed has been used in traditional European and Middle Eastern herbal practice as both a food and a medicinal seed. The phytoestrogenic properties of flaxseed components, especially lignans and their biotransformation products enterodiol (END) and enterolactone (ENL), have been subjects of analysis in experimental, clinical, and epidemiological contexts. Flaxseed is the richest vegetable source of lignans (up to 0.7–1.5% of dry weight of seed), among which secoisolariciresinol diglycoside (SIR-DG) predominates.

Scientific Evidence

Epidemiological data suggest that phytoestrogens have a preventive effect against various estrogen-related diseases and symptoms such as breast cancer, menopausal symptoms, cardiovascular diseases, and osteoporosis. To probe these associations, available controlled clinical trials have been critically reviewed. Especially soy isoflavones have been extensively studied. However, reviewed clinical trials do not provide consistent scientific evidence for an effect of phytoestrogens on menopausal symptoms and risk factors of breast cancer. Isoflavone-containing soy protein can lower total cholesterol, LDL cholesterol, and triglyceride serum levels. The strongest clinical evidence exists for a preventive effect of soy isoflavones on postmenopausal bone loss of the lumbar spine.

Distinct effects on estrogen-related diseases can be explained at least in part by the different affinity of isoflavones to estrogen receptors alpha and beta and the distinct tissue distribution of these receptors.

Regarding flaxseed, a clinical, randomized, controlled trial in 46 postmenopausal women supplemented with either a placebo, soy, or flaxseed for 16 weeks showed that urinary concentrations of 2-hydroxyestrone increased significantly in the flaxseed group. In the soy and placebo groups, no significant correlation was observed.

Evidence strength: Overall, evidence for phytoestrogens is mixed. Bone-related outcomes in postmenopausal women are the best-supported finding. Effects on hot flashes and breast cancer risk markers are inconsistent across clinical trials. The overall impact may depend on age, health status, and the presence or absence of specific gut microflora. Clarity on these issues is needed because global consumption is rapidly increasing.

7.2 Indole-3-Carbinol (I3C) and 3,3′-Diindolylmethane (DIM)

Traditional Use

I3C and DIM are not traditional herbal preparations in the historical sense; rather, they are bioactive compounds derived from cruciferous vegetables (broccoli, cauliflower, kale, Brussels sprouts, cabbage), which have long featured in Mediterranean, Northern European, and Asian diets. The specific medicinal use of concentrated I3C or DIM supplements is a modern development emerging from late-20th-century nutritional biochemistry research.

Scientific Evidence

Cruciferous vegetables such as Brussels sprouts, broccoli, kale, cabbage, and cauliflower are rich sources of the dietary bioactive compounds indole-3-carbinol (I3C) and its major metabolite 3,3′-diindolylmethane (DIM). 3,3′-Diindolylmethane has been recognized as the major in vivo derivative responsible for most of the biological properties of indole-3-carbinol. Chewing or chopping cruciferous vegetables results in the hydrolysis of the glucosinolate glucobrassicin into indole-3-carbinol, catalyzed by the enzyme myrosinase.

DIM has multiple mechanisms of action; the most well-characterized is modulation of aryl hydrocarbon receptor (AhR) signaling. In humans, much of the research focus has been on chemoprevention of breast and prostate cancer. Alteration of cytochrome P450-dependent estrogen metabolism is hypothesized to be an important driver of DIM-dependent breast cancer prevention.

Interest in integrative and functional medicine approaches to women's health has led dietary supplements such as I3C and DIM to gain attention for their potential impact on estrogen metabolism. A large body of evidence suggests that DIM, a dimer of I3C found in cruciferous vegetables, can potentially prevent carcinogenesis, tumor development, and shift estrogen metabolism in healthy postmenopausal women.

3,3′-Diindolylmethane (DIM), a major phytochemical derived from ingestion of cruciferous vegetables, is also available as a dietary supplement. In preclinical models, DIM is an effective cancer chemopreventive agent and has been studied in a number of clinical trials. Systematic reviews have identified 22 human clinical studies reporting original data on the effect of supplementation with DIM or DIM-precursors.

Evidence strength: The evidence base for I3C and DIM in modulating estrogen metabolism is biologically plausible and supported by preclinical and preliminary human data, but clinical trial results are still limited in scale and consistency. The human evidence for cancer chemoprevention remains exploratory.

7.3 Black Cohosh (Actaea/Cimicifuga racemosa)

Traditional Use

Black cohosh is a perennial plant native to North America. Indigenous peoples of the eastern woodlands — including the Cherokee, Iroquois, and other tribes — used the rhizome and root of this plant for a wide range of gynecological conditions including menstrual irregularity and symptoms associated with menopause. The herb was subsequently adopted into 19th-century North American eclectic medicine and later popularized in Europe, especially Germany, where standardized extracts (e.g., Remifemin) have been widely used for menopausal symptom relief since the 1950s.

Scientific Evidence

The rhizome of black cohosh contains a number of biologically active constituents, including the triterpene glycosides actein and cimicifugoside, as well as fatty acids, resins, caffeic acids, isoferulic acids, and isoflavones. Serotonergic mechanisms similar to those of antidepressants have been proposed for Actaea/Cimicifuga racemosa (black cohosh). Black cohosh has been reported to act in a non-estrogenic manner, binds to estrogen receptors, and selectively suppresses luteinizing hormone secretion with no effect on follicle-stimulating hormone.

A meta-analysis involving four randomized clinical trials on black cohosh indicated that three of the four trials found black cohosh helpful in treating menopausal symptoms. Black cohosh reduces hot flashes and night sweats most effectively. It is important to note that the fourth trial did not show a significant improvement with black cohosh treatment.

In one well-cited randomized, double-blind, placebo-controlled clinical trial, conducted on 84 early postmenopausal participants, participants were randomly allocated into a treatment group receiving 6.5 mg of dried extract of black cohosh roots daily and a placebo group, and took one tablet per day for 8 weeks. Black cohosh reduced the Greene Climacteric Scale total score and all subscale scores (vasomotor, psychiatric, physical, and sexual symptoms) during 4 and 8 weeks of treatment.

In summary, black cohosh shows promise for relief of menopausal symptoms, primarily for treatment of vasomotor symptoms and possibly mood, with an overall positive safety profile for at least six months and likely longer.

Evidence strength: Moderate. The most consistent clinical finding is improvement in vasomotor symptoms (hot flashes, night sweats). Evidence for effects on estrogen levels per se is less clear, and the mechanism of action remains debated. Standardized extract studies show generally positive but not uniformly significant results.

7.4 Chasteberry (Vitex agnus-castus)

Traditional Use

Chasteberry, the fruit of Vitex agnus-castus, has been used in herbal medicine for millennia. Its documented use traces to ancient Greece, where Hippocrates and Dioscorides referenced it for gynecological purposes. It was used throughout the Middle Ages in European monastic settings to suppress libido (hence the name "chasteberry"). In traditional European phytomedicine, it has been used primarily for menstrual irregularities, premenstrual syndrome, and corpus luteum insufficiency.

Scientific Evidence

Chasteberry extracts have been shown to have ERα-dependent estrogenic activity. It was also shown that chasteberry extract selectively bound ERβ, and bioassay-guided fractionation resulted in the isolation of the weak ERβ ligand apigenin. These data suggest that linoleic acid from the fruits of Vitex agnus-castus can bind to estrogen receptors and induce certain estrogen-inducible genes.

Some research has suggested that chasteberry might reduce PMS symptoms such as breast pain or tenderness, but higher-quality evidence is needed to reach any definitive conclusions. One study suggested that chasteberry might reduce heavy menstrual bleeding related to an intrauterine device (IUD), but the evidence is of low quality. There is not enough reliable evidence to know if chasteberry would help with sexual dysfunction or infertility.

Much research has been conducted on the safety of this herb and has determined that chasteberry supplementation may not be safe for women with hormone-sensitive conditions, such as breast, uterine, or ovarian cancer.

Evidence strength: Limited to moderate. The NCCIH acknowledges that higher-quality evidence is needed. The most studied application is PMS symptom relief. The estrogenic receptor-binding activity documented in vitro does not yet have direct clinical correlates for estrogen balance specifically.

7.5 Other Botanicals Traditionally Used in Women's Hormonal Health

Many other botanicals are commonly used for menopause and menopause-related complaints, including licorice root (Glycyrrhiza glabra), dong quai (Angelica sinensis), wild yam (Dioscorea villosa), evening primrose (Oenothera biennis), ginkgo (Ginkgo biloba), ginseng (Panax ginseng), valerian (Valeriana officinalis), motherwort (Leonurus cardiaca), and St. John's Wort (Hypericum perforatum). Rigorous clinical trials for most of these botanicals in the context of PMS and hormonal balance have not been completed.

8. Dietary Factors

8.1 Dietary Fiber

More than two decades ago, dietary fiber was hypothesized to lower the risk of breast cancer, based on findings suggesting that vegetarian women had increased fecal excretion of estrogens and decreased plasma concentration of estrogen compared with omnivorous women. Dietary fiber could protect against breast cancer through inhibition of the intestinal reabsorption of estrogens excreted by the biliary system and an increase in fecal excretion of estrogens; both mechanisms could lower circulating estrogen levels.

In an intervention study, the effect of dietary fiber on serum estrogen concentrations was studied in 62 premenopausal women whose estimated daily dietary fiber intake was increased from approximately 15 g to 30 g/d by supplementation with wheat, oat, or corn bran, without any significant decrease in dietary fat consumption. After 2 months on the high-fiber diets, the wheat-bran-supplemented group showed significant reductions in serum estrone and estradiol but no change in serum progesterone or sex-hormone-binding globulin concentrations. Serum estrogens were unaffected by dietary fiber supplementation with oat or corn brans, indicating that the type of fiber matters and that results are not universally generalizable.

8.2 Cruciferous Vegetables

Epidemiological studies have shown that consumption of cruciferous vegetables significantly lowers the incidence of human cancer. This association is attributed in part to the I3C/DIM pathway described above, which influences cytochrome P450-mediated estrogen metabolism. The evidence is primarily epidemiological and mechanistic; large randomized trials specifically targeting the estrogen-balancing effect of dietary cruciferous vegetable consumption are limited.

8.3 Alcohol

Alcohol is believed to increase the aromatization of testosterone into estrogen through hepatic stimulation of the enzyme aromatase. Even when consumed within the recommended limits of up to one drink per day, alcohol is associated with a dose-dependent risk of developing estrogen receptor-positive breast cancer, the most common cancer among women.

8.4 Dietary Fat and Overall Diet Quality

Reproductive factors and body fatness, which affect estrogen, progesterone, and insulin status, have been identified as risk factors for breast cancer. In addition, intakes of dietary fat and alcohol, which have been implicated in estrogen metabolism, have been related to an increased risk of breast cancer. Higher levels of the estrogen metabolite 16-hydroxyestrone are associated with inflammation, excess levels of omega-6 fatty acids, obesity, hypothyroidism, and pesticide toxicity.

9. Lifestyle Factors

9.1 Body Weight and Adiposity

Estrogen is produced in adipose tissue by the aromatization of androgen to estrogen by aromatase. Aromatase is found in white adipose tissue. Women with higher amounts of fat have higher levels of aromatase; thus, obese postmenopausal women have higher estrogen levels than lean postmenopausal women. This pathway makes body weight management a recognized factor in discussions of postmenopausal estrogen exposure.

9.2 Environmental Exposure Reduction

Synthetic xenoestrogens are generally pervasive and widely dispersed in the environment and may bioaccumulate. One of the most widely diffused and dangerous synthetic xenoestrogens is bisphenol A (BPA), which is widely produced and largely diffused in foodstuff, such as plastic bottles and thermal paper. BPA, a xenoestrogen widely used in the plastic food packaging industry, has been shown to affect many physiological functions and has been linked to reproductive, endocrine, and metabolic disorders and cancer. The widespread use of BPA during the last 30 years could have contributed to the increased incidence of metabolic diseases.

9.3 Gut Health and Microbiome Diversity

One of the principal regulators of circulating estrogens is the gut microbiome. External factors such as nutrition, physical activity, and obesity can alter microbiome composition and potentially shift functions towards greater estrogen recycling. A diet high in fiber and diverse plant foods is associated with greater microbial diversity, which in turn may support more balanced estrobolome activity, though direct human clinical evidence for this specific chain of causation remains incomplete.

10. Evidence Gaps and Scientific Caveats

The concept of estrogen balance, as used in nutritional and natural-health contexts, bridges well-established endocrinology with areas of ongoing and incomplete investigation. Several important caveats apply:

• Estrogen dominance is not a recognized clinical diagnosis. "Currently, estrogen dominance is not recognized as a medical condition." Its utility lies in describing a relative hormonal pattern rather than a discrete, measurable threshold.
• Phytoestrogens show mixed clinical results. The impact of phytoestrogens is likely complex and may depend on age, health status, and even the presence or absence of specific gut microflora.
• The estrobolome hypothesis is scientifically compelling but not yet fully characterized in humans. Findings from case-control studies were heterogeneous and showed limited alignment with estrobolome targets. The lack of compelling evidence for estrobolome-specific mechanisms may reflect measurement challenges, or may suggest that broader ecological changes in the microbiome are more influential for carcinogenesis.
• Most herbal evidence is preliminary. For black cohosh, chasteberry, and most other botanicals, randomized controlled trial data are limited in scale and consistency, and mechanisms of action on estrogen pathways specifically are not fully established.
• Most DIM/I3C data are preclinical. DIM is an effective cancer chemopreventive agent in preclinical models and has been studied in a number of clinical trials, but large-scale, long-term human data are still lacking.

References

• Hewitt SC, Korach KS. Estrogen Hormone Biology. Current Topics in Developmental Biology. PMC6206851.
• Li R, et al. Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective. PMC10504839.
• Mauvais-Jarvis F, et al. The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis. Endocrine Reviews. PMC3660717.
• Patel S, et al. Estrogen: The necessary evil for human health, and ways to tame it. Pathophysiology. PubMed 29573619.
• Ogawa S, Inoue S, et al. Functions and physiological roles of two types of estrogen receptors, ERα and ERβ. FEBS Letters. PMC3389841.
• U.S. Department of Veterans Affairs. Estrogen Dominance. Whole Health Library.
• Zhang X, et al. Gut microbiota has the potential to improve health of menopausal women by regulating estrogen. PMC12183514.
• Larnder A, et al. The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer. International Journal of Cancer. PMC12178105.
• Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. PMC10416750.
• Baker JM, et al. Estrogen–gut microbiome axis: Physiological and clinical implications. Maturitas. 2017.
• Auborn KJ, et al. Exploring the impact of 3,3'-diindolylmethane on the urinary estrogen profile of premenopausal women. PMC11583660.
• Dashwood RH, et al. Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3'-Diindolylmethane. PMC8517077.
• Yerushalmi R, et al. 3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. Carcinogenesis. 2020.
• Thomson CA, et al. Anti-Cancer and Other Biological Effects of a Dietary Compound 3,3′-Diindolylmethane Supplementation: A Systematic Review of Human Clinical Trials. Nutrition and Dietary Supplements. 2020.
• Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. Frontiers in Neuroendocrinology. PMC3074428.
• Setchell KD, Cassidy A. [Phytoestrogens]. PubMed 14556117.
• Paterni I, et al. Exploring the Biological Activity and Mechanism of Xenoestrogens and Phytoestrogens in Cancers: Emerging Methods and Concepts. PMC8395949.
• Caserta D, et al. Risks and benefits related to alimentary exposure to xenoestrogens. PMC6104637.
• Mathur PP, et al. [The environmental estrogen bisphenol A and its effects on the human organism]. PubMed 23808741.
• Newbold RR, et al. Environmental Estrogens and Obesity. PMC2682588.
• Al-Hussaini TK, et al. Exploring the Efficacy and Safety of Black Cohosh (Cimicifuga racemosa) in Menopausal Symptom Management. PMC11100637.
• Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms (Cochrane Review). PMC6599854.
• Shahnazi M, et al. Efficacy of black cohosh (Cimicifuga racemosa L.) in treating early symptoms of menopause: a randomized clinical trial. PMC4029542.
• National Center for Complementary and Integrative Health (NCCIH). Chasteberry: Usefulness and Safety.
• Dietz BM, et al. Botanicals and Their Bioactive Phytochemicals for Women's Health. PMC5050441.
• Huntley AL. Contemporary Alternatives to Plant Estrogens for Menopause. PMC1780040.
• Rice MS, et al. Alcohol consumption, endogenous estrogen and mammographic density among premenopausal women. PMC4531831.
• Bhatt DL, et al. Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study. PMC11720806.
• Dong JY, et al. Dietary fiber intake and risk of breast cancer in postmenopausal women: the NIH–AARP Diet and Health Study. PMC2728649.
• Rose DP, et al. High-fiber diet reduces serum estrogen concentrations in premenopausal women. PubMed 1652197.
• Frontiers in Endocrinology. The impact of estrogen status on the gut microbiome: a systematic review and meta-analysis. 2026.